Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
2021 · New England Journal of Medicine · 1,677 citations
https://doi.org/10.1056/nejmoa2032125
A
Andrew H. Ko
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
299
Papers
17.1K
Citations
49
h-index
107
i10-index
Andrew H. Ko is an academic researcher. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers. The author has an h-index of 49, co-authored 255 publications.
ORCID: 0000-0001-8196-7907Papers by this author
worksPancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
2021 · Journal of the National Comprehensive Cancer Network · 1,198 citations
https://doi.org/10.6004/jnccn.2021.0017
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
2019 · Clinical Cancer Research · 250 citations
https://doi.org/10.1158/1078-0432.ccr-18-2992
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
2005 · British Journal of Cancer · 162 citations
https://doi.org/10.1038/sj.bjc.6602687
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
2013 · British Journal of Cancer · 158 citations
https://doi.org/10.1038/bjc.2013.408
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat